RBM15B and COVID-19: COVID-19 patients with elevated expression levels of CBLL1, METLL16, and RBM15B presented elevated expression levels of ALKBH5 while elevated METTL14 and ZC3H13 expression demonstrated a negative association with ALKBH5 (Figures 2F–J).